The effects of intracerebroventricularly injected corticotropin-releasing factor (CRF) on the central nervous system: Behavioural and biochemical studies

doi:10.1016/0143-4179(89)90085-1

Neuropeptides

Volume 13, Issue 3, April 1989, Pages 147-155

https://doi.org/10.1016/0143-4179(89)90085-1 Get rights and content

Abstract

Intracerebroventricularly (ICV) administered corticotropin-releasing factor (CRF) produces behavioural activation in rats. The present study was designed to investigate the effects of ICV administered CRF on not only locomotor activity, but also the turnover rates of dopamine (DA) and norepinephrine (NE) in various discrete brain regions in rats. ICV administration of 1 μg CRF produced a significant increase in locomotor activity, while ICV administration of 10 μg CRF caused slow stereotypy with prominent grooming. The 3,4-dihydroxyphenylacetic acid/DA ratio, e.g. DA utilization, was increased in the frontal cortex (FC), striatum, hippocampus (HIPP) and amygdala. DA utilization in the FC increased in a dose dependent manner, suggesting that the hyperactivity of the mesocortical DA system is relevant to the grooming response. The 3-methoxy-4-hydroxy-phenylglycol/NE ratio was increased in the FC and HIPP, indicating the involvement of the dorsal NE pathway in ICV CRF-induced behavioural changes in rats. These findings are discussed in connection with the hypothesis that CRF produces behavioural changes consistent with increasing emotionality, especially anxiety, and may serve as a neuroendocrine modulator of stress-enhanced behaviour.

References (28)

D.R. Britton et al.
Intraventricular corticotropin-releasing factor enhances behavioural effects of novelty
Life Sciences
(1982)
K.T. Britton et al.
Activating and “anxiogenic” effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone
Life Sciences
(1986)
K.T. Britton et al.
Corticotropin releasing factor (CRF) receptor antagonist blocks activating and “anxiogenic” actions of CRF in the rat
Brain Research
(1986)
D.J.S. Sirinathsinghji
Inhibitory influence of corticotropin releasing factor on components of sexual behaviour in the male rat
Brain Research
(1987)
M.R. Brown et al.
Corticotropin-releasing factor: Effects on the sympathetic nervous system and oxygen consumption
Life Sciences
(1982)
R.J. Valentino et al.
Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus
Brain Research
(1983)
M. Ikeda et al.
Reflectance of rat brain structures mapped by an optical fiber technique
Journal of Neuroscience Methods
(1980)
J.A. Harvey
Behavioural pharmacology of central nervous system stimulants
Neuropharmacology
(1987)
P.H. Kelly et al.
Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum
Brain Research
(1975)
S. Tam et al.
Selective increase in dopamine metabolism in the prefrontal cortex by the anxiogenic beta-carboline FG7142
Biochemical Pharmacology
(1985)

S.J. Grant et al.

Benzodiazepines attenuate single unit activity in the locus coeruleus

Life Sciences

(1980)

J. Korf et al.

Alternations in turnover and endogenous levels of norepinephrine in cerebral cortex following electrical stimulation and acute axotomy of cerebral noradrenergic pathways

European Journal of Pharmacology

(1973)

D.D. Krahn et al.

Behavioural effects of corticotropin-releasing factor: localization and characterization of central effects

Brain Research

(1988)

W. Vale et al.

Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and betaendorphin

Science

(1981)

Cited by (89)

Four hypothalamic peptides and their impact on drug-seeking behaviour: A prefrontal cortex view
2022, Addiction Neuroscience
The prefrontal cortex plays a critical role in regulating substance use disorder and is strongly implicated in inhibition of and relapse to drug-seeking. Within the prefrontal cortex, inhibitory interneurons make up tightly regulated microcircuits that moderate activity of pyramidal neurons and hence control output to downstream circuits including those important for addiction-related behaviours. These interneurons can be classed into subpopulations based on peptide expression, however the complexity of these subclasses is only beginning to be understood. In this review we focus on four peptides that have receptor expression on interneurons and pyramidal neurons in the PFC. All four peptides have well-known roles in mediating drug-seeking behaviours, however their function within the prefrontal cortex is less well defined. We will review evidence from preclinical animal models that cells expressing these receptors are recruited during addiction-related behaviours, and that direct pharmacological manipulation of these systems within the prefrontal cortex may lead to altered drug-seeking behaviours. In our view, a deeper understanding of activity of specific microcircuits within this region, and their effect on pyramidal neuronal output are critical for understanding and remediating specific behaviours relevant to substance use disorder. Uncovering function of cells populations that express these neuropeptides and their receptors may help to define these microcircuits, and hence to understand how and why these behaviours are altered following drug exposure.
Central CRF and acute stress differentially modulate probabilistic reversal learning in male and female rats
2021, Behavioural Brain Research
Acute stress can have variable and sometimes sex-dependent effects on different executive functions, including cognitive flexibility, some of which may be mediated by increased corticotropin releasing factor (CRF). Previous studies on the effects of stress and CRF on cognitive flexibility have used procedures entailing deterministic rewards, yet how they may alter behavior when outcomes are probabilistic is unclear. The present study examined how acute stress and increased CRF activity alters probabilistic reversal learning (PRL) in male and female rats. Rats learned to discriminate between a ‘correct’ lever rewarded on 80 % of trials, and an “incorrect” lever delivering reward on 20 % of trials, with reward contingencies reversed after 8 consecutive correct choices. Separate groups received either intracerebroventricular infusions of CRF (3 μg) or restraint stress prior to a PRL session. Experiments examined how these manipulations affected learning when given prior to a one-day acquisition test or during performance in well-trained rats. Exogenous CRF, and to a lesser extent acute stress, impaired motivation across sexes, slowing deliberation times and increasing the number of trials omitted, particularly following a switch in reward contingencies. Neither manipulation significantly altered errors or reversal performance. However, increased CRF activity reduced negative feedback sensitivity. Across manipulations, females showed increased omissions and choice latencies, and were less sensitive to feedback than males. These results reveal the complexity with which stress, CRF, sex, and experience interact to alter aspects of motivation and probabilistic reinforcement learning and provide insight into how CRF activity may contribute to symptoms of stress-related disorders.
Corticotropin-Releasing Factor (CRF) circuit modulation of cognition and motivation
2019, Neuroscience and Biobehavioral Reviews
Citation Excerpt :
This is supported by observations that central administration of a CRF1 receptor antagonist increases the number of spontaneously active DA neurons (Lodge and Grace, 2005), which drives slower, extrasynaptic or “tonic” DA levels within the NAc (Floresco et al., 2003). With respect to CRF effects on different modes of DA release, microdialysis studies demonstrate that centrally administered CRF increases tonic DA release in the NAc (Dunn and Berridge, 1987; Matsuzaki et al., 1989; Kalivas and Duffy, 1995), and blockade of VTA CRF2 receptors attenuates increases in mesoaccumbens DA release induced by social defeat stress (Holly et al., 2015). Moreover, administration of CRF on NAc slices in vitro potentiates evoked DA release, suggesting that it may facilitate DA transmissions via local mechanisms within this nucleus (Lemos et al., 2012).
The neuropeptide, corticotropin-releasing factor (CRF), is a key modulator of physiological, endocrine, and behavioral responses during stress. Dysfunction of the CRF system has been observed in stress-related affective disorders including post-traumatic stress disorder, depression, and anxiety. Beyond affective symptoms, these disorders are also characterized by impaired cognition, for which current pharmacological treatments are lacking. Thus, there is a need for pro-cognitive treatments to improve quality of life for individuals suffering from mental illness. In this review, we highlight research demonstrating that CRF elicits potent modulatory effects on higher-order cognition via actions within the prefrontal cortex and subcortical monoaminergic and cholinergic systems. Additionally, we identify questions for future preclinical research on this topic, such as the need to investigate sex differences in the cognitive and microcircuit actions of CRF, and whether CRF may represent a pharmacological target to treat cognitive dysfunction. Addressing these questions will provide new insight into pathophysiology underlying cognitive dysfunction and may lead to improved treatments for neuropsychiatric disorders.
Characterization of CRF<inf>1</inf> receptor antagonists with differential peripheral vs central actions in CRF challenge in rats
2017, Peptides
Citation Excerpt :
Compound B did not show binding affinity to cortex and did not suppress locomotion (Fig. 6B). In addition, anxiety behavior was reported to have relationship with cortical CRF signaling [27]. Therefore we did not examine Compound B because cortical suppression may be critical for the central-modulated changes by CRF [16].
The aim of this study was to investigate peripheral and central roles of corticotropin-releasing factor (CRF) in endocrinological and behavioral changes. Plasma adrenocorticotropin (ACTH) concentration was measured as an activity of hypothalamic-pituitary-adrenal (HPA) axis. As behavioral changes, locomotion and anxiety behavior were measured after CRF challenge intravenously (i.v.) for the peripheral administration or intracerebroventricularly (i.c.v.) for the central administration. Plasma ACTH concentration was significantly increased by both administration routes of CRF; however, hyperlocomotion and anxiety behavior were induced only by the i.c.v. administration. In the drug discovery of CRF₁ receptor antagonists, we identified two types of compounds, Compound A and Compound B, which antagonized peripheral CRF-induced HPA axis activation to the same extent, but showed different effects on the central CRF signal. These had similar in vitro CRF₁ receptor binding affinities (15 and 10 nM) and functional activities in reporter gene assay (15 and 9.5 nM). In the ex vivo binding assays using tissues of the pituitary, oral treatment with Compound A and Compound B at 10 mg/kg inhibited [¹²⁵I]-CRF binding, whereas in the assay using tissues of the frontal cortex, treatment of Compound A but not Compound B inhibited [¹²⁵I]-CRF binding, indicating that only Compound A inhibited central [¹²⁵I]-CRF binding. In the peripheral CRF challenge, increase in plasma ACTH concentration was significantly suppressed by both Compound A and Compound B. In contrast, Compound A inhibited the increase in locomotion induced by the central CRF challenge while Compound B did not. Compound A also reduced central CRF challenge-induced anxiety behavior and c-fos immunoreactivity in the cortex and the hypothalamic paraventricular nucleus. These results indicate that the central CRF signal, rather than the peripheral CRF signal would be related to anxiety and other behavioral changes, and CRF₁ receptor antagonism in the central nervous system may be critical for identifying drug candidates for anxiety and mood disorders.
Low stress reactivity and neuroendocrine factors in the BTBR T<sup>+</sup>tf/J mouse model of autism
2010, Neuroscience
Autism is a neurodevelopmental disorder characterized by abnormal reciprocal social interactions, communication deficits, and repetitive behaviors with restricted interests. BTBR T+tf/J (BTBR) is an inbred mouse strain that displays robust behavioral phenotypes with analogies to all three of the diagnostic symptoms of autism, including low social interactions, reduced vocalizations in social settings, and high levels of repetitive self-grooming. Autism-relevant phenotypes in BTBR offer translational tools to discover neurochemical mechanisms underlying unusual mouse behaviors relevant to symptoms of autism. Because repetitive self-grooming in mice may be a displacement behavior elevated by stressors, we investigated neuroendocrine markers of stress and behavioral reactivity to stressors in BTBR mice, as compared to C57BL/6J (B6), a standard inbred strain with high sociability. Radioimmunoassays replicated previous findings that circulating corticosterone is higher in BTBR than in B6. Higher basal glucocorticoid receptor mRNA and higher oxytocin peptide levels were detected in the brains of BTBR as compared to B6. No significant differences were detected in corticotrophin releasing factor (CRF) peptide or CRF mRNA. In response to behavioral stressors, BTBR and B6 were generally similar on behavioral tasks including stress-induced hyperthermia, elevated plus-maze, light ↔ dark exploration, tail flick, acoustic startle and prepulse inhibition. BTBR displayed less reactivity than B6 to a noxious thermal stimulus in the hot plate, and less immobility than B6 in both the forced swim and tail suspension depression-related tasks. BTBR, therefore, exhibited lower depression-like scores than B6 on two standard tests sensitive to antidepressants, did not differ from B6 on two well-validated anxiety-like behaviors, and did not exhibit unusual stress reactivity to sensory stimuli. Our findings support the interpretation that autism-relevant social deficits, vocalizations, and repetitive behaviors are not the result of abnormal stress reactivity in the BTBR mouse model of autism.
Rhythmic clock and neuropeptide gene expression in hypothalamic mHypoE-44 neurons
2010, Molecular and Cellular Endocrinology
The rhythmic expression of specific clock genes: Bmal1, Per2, Clock and Rev-Erbα; and specific hypothalamic neuropeptides: NPY, Crh, AgRP, neurotensin and preproghrelin, expressed in clonal hypothalamic neuronal cell lines, was assayed and analyzed using a novel non-linear least squares statistical analysis to determine rhythmicity in an in vitro milieu. In silico analysis of the neuropeptide promoter regions identified putative E-box motifs and a motif in the NPY promoter is bound to in an oscillatory fashion. Within the mHypoE-44 neurons, we demonstrate that mRNA of four core circadian components: Bmal1, Clock, Per2 and Rev-Erbα, oscillate with approximate 24 h rhythms. NPY and NT demonstrated significant 24 h gene expression. However, CRH and preproghrelin mRNA cycled significantly in an ultradian fashion, oscillating approximately every 18 h. AgRP mRNA did not show a significant rhythm. We speculate that endogenous rhythmic neuropeptide expression contributes to neuroendocrine homeostasis, which may include energy balance.

View all citing articles on Scopus

View full text

The effects of intracerebroventricularly injected corticotropin-releasing factor (CRF) on the central nervous system: Behavioural and biochemical studies

Abstract

Life Sciences

Life Sciences

Brain Research

Brain Research

Life Sciences

Brain Research

Journal of Neuroscience Methods

Neuropharmacology

Brain Research

Biochemical Pharmacology

Life Sciences

European Journal of Pharmacology

Brain Research

Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and betaendorphin

Science